

21 March 2023

To: Recipients of M100, 33rd ed.
 From: Jennifer K. Adams, MLS(ASCP), MSHA
 Vice President, Standards and Quality
 Subject: Corrections

This notice is intended to inform users of corrections made to CLSI document M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 33rd ed. The corrections are described below and shown as stricken and highlighted text in the applicable sections and table excerpts.

Table of Contents

Table 1A. Enterobacterales (not including ~~inducible AmpC producers and~~ *Salmonella/Shigella*)

Overview of Changes

| Tables 1. Antimicrobial Agents That Should Be Considered for Testing and Reporting by Microbiology Laboratories | |
|--|---|
| Table 1A. Enterobacterales (not including inducible AmpC producers and <i>Salmonella/Shigella</i>) (new table) | Added: <ul style="list-style-type: none"> Antimicrobial agents for Enterobacterales (not including inducible AmpC producers and <i>Salmonella/Shigella</i>) (pp. 26-27) |

Table 1A. Enterobacterales (not including ~~inducible AmpC producers and~~ *Salmonella/Shigella*)

| | | | |
|--|--|---|--|
| Tier 1: Antimicrobial agents that are appropriate for routine, primary testing and reporting | Tier 2: Antimicrobial agents that are appropriate for routine, primary testing but may be reported following cascade reporting rules established at each institution | Tier 3: Antimicrobial agents that are appropriate for routine, primary testing in institutions that serve patients at high risk for MDROs but should only be reported following cascade reporting rules established at each institution | Tier 4: Antimicrobial agents that may warrant testing and reporting by clinician request if antimicrobial agents in other tiers are not optimal because of various factors |
|--|--|---|--|

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.